At the conclusion of this conference, attendees will be expected to: (1) identify key factors increasing disease penetrance in females, (2) identify key factors increasing disease penetrance in carriers of the BMPR2+/- mutation, (3) identify risk factors that can be targeted pharmacologically as novel therapeutic strategies, and (4) assess the relevance of genetic and environmental risk factors on the responsiveness of patients to current and emerging therapies.
For information and registration please visit the Conference Website